98 results
424B3
SLGL
Sol-Gel Technologies Ltd
20 May 24
Prospectus supplement
4:05pm
revenue for the first quarter of 2023 was revised as reflected in the below income statement.
Research and development expenses were $5.3 million compared … financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we
6-K
EX-99.1
SLGL
Sol-Gel Technologies Ltd
20 May 24
Sol-Gel Reports First Quarter 2024 Financial Results and Provides
7:15am
, previously reported revenue for the first quarter of 2023 was revised as reflected in the below income statement.
Research and development expenses … substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution
6-K
EX-99.1
SLGL
Sol-Gel Technologies Ltd
16 May 24
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to
6:15am
) intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory
424B3
SLGL
Sol-Gel Technologies Ltd
4 Apr 24
Prospectus supplement
9:05am
the Registered Direct Offering to fund the acquisition of SGT-610 and intend to use the balance of the net proceeds for research and development activities … , technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do;
potential
6-K
EX-99.1
SLGL
Sol-Gel Technologies Ltd
1 Apr 24
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to
7:15am
substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel
POS AM
sczo7ir9em 2f15kn0dj
20 Mar 24
Prospectus update (post-effective amendment)
4:05pm
6-K
EX-99.1
os4jq44f sbapk
13 Mar 24
Sol-Gel Reports Full-Year 2023 Financial Results and 2023 - Corporate Highlights and Recent Developments
8:34am
6-K
EX-99.1
j0vm0
30 Nov 23
Current report (foreign)
7:10am
424B3
ohy6v9 f0gbypck
9 Nov 23
Prospectus supplement
3:41pm
6-K
EX-99.1
nvzwf8ses3c uxjc3ydx
9 Nov 23
Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update
7:15am
424B3
ekf6pmxz gn7y52
10 Aug 23
Prospectus supplement
7:20am
6-K
EX-99.1
v5hwkaa
10 Aug 23
Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:10am
6-K
EX-99.2
l5m8dp
10 Aug 23
Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:10am
6-K
EX-99.1
qd4oacniht2 zbw
21 Jun 23
Notice of Annual Meeting of Shareholders
9:38am
6-K
EX-99.1
jqxsdiptvt
6 Jun 23
Sol-Gel and Searchlight Pharma Announce Licensing Agreements to
7:15am
424B3
kevpsmiu9d
12 May 23
Prospectus supplement
9:15am
6-K
EX-99.1
pu7uxtbpexs6z8z67
12 May 23
Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides
12:00am
6-K
EX-99.1
wf3j036t8qs6ha 0k
21 Nov 22
Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:42pm
6-K
EX-99.1
cwx3y9dx8sj
3 Oct 22
Sol-Gel Technologies Appoints Michael Glezin Vice
8:05am